Conjugating antibody to drug using ThioBridge technology for better ADCs

In this application note, explore how ThioBridge^®, a conjugation technology, enables precise and site-specific modification of antibody interchain disulfide bonds, without the need for antibody engineering. As a next-generation approach, ThioBridge addresses the shortcomings of first-generation conjugation technologies, allowing more homogeneous, reproducible antibody–drug conjugates (ADC) constructs with a more uniform drug–antibody ratio (DAR) profile compared to first-generation technologies.